Background {#Sec1}
==========

Breast cancer (BC) is the most common cancer in women, accounting for around 25% of all new cases of cancer \[[@CR1]\]. Most BC cases are sporadic, while 5 to 10% of all BC cases are inherited and cluster in families \[[@CR1]\]. While mutations in *BRCA1* and *BRCA2* genes explain 16--40% of all familial BC cases \[[@CR1]--[@CR3]\], other genes have also been found to increase BC susceptibility, which highlights the polygenic nature of many BC cases \[[@CR4]\]. Some of these genes including *CDH1*, *TP53*, *PTEN* and *STK11,* although less frequently altered compared to the *BRCA1/2* genes, they have been linked to high-penetrance autosomal dominant BC \[[@CR5]--[@CR7]\]. Moderate penetrance genes are implicated in around 5% of familial BC. These genes include the Fanconi anemia pathway genes: *FANCA*, *PALB2*, *BRIP1*, *RAD51C* and *XRCC2* \[[@CR8]--[@CR10]\] and non-Fanconi anemia genes: *ATM*, *CHEK2*, *NBN*, *RAD50*, *RAD51B*, and *RAD51D* \[[@CR11]--[@CR15]\].

In Lebanon, BC is the most common cancer type in females and it constitutes one-third of all reported cancer cases. BC incidence rates are expected to reach 137 per 100,000 by 2018 \[[@CR16]\]. Yet, to date, only two studies have investigated the role of *BRCA1* and *BRCA2* mutations in the Lebanese population. These studies reported varied prevalence of pathogenic *BRCA* mutations ranging between 5.6 to 12.5% in BC cases \[[@CR17], [@CR18]\]. The reported prevalences of both *BRCA1* and *BRCA2* deleterious mutations were lower than those reported for the Western populations, which suggest the involvement of other genes in the pathogenesis of BC cases \[[@CR19]\]. The reported low prevalence does not support the hypothesis that *BRCA1* and *BRCA2* mutations alone are responsible for the majority of the observed Lebanese women with early-onset BC. This finding could well explain the fact that BC is a disease with a high level of genetic heterogeneity and that monogenic and polygenic models of inheritance may exist.

Since the completion of the human genome project, massive leaps have reshaped the field of clinical genomics. The development of Next-generation sequencing (NGS) platforms allowed a more robust, fast and accurate analysis of diseases and syndromes with polygenic nature. NGS platforms including WES are believed to enhance and improve diagnosis and therapy development of many diseases including BC \[[@CR20]--[@CR23]\].

In the presented study, we utilized WES to investigate germline genetic variations in 45 Lebanese cases diagnosed with familial BC and unknown *BRCA1* or *BRCA2* status. We found several rare variants that can potentially explain BC susceptibility in the analyzed cases.

Methods {#Sec2}
=======

Inclusion criteria {#Sec3}
------------------

From 2012 to 2015, 45 unrelated patients with inherited BC were selected to undergo DNA testing. They were referred from a wide variety of settings from all over the country, ranging from private physicians' clinics to major academic medical centers because of hereditary BC. The patients fulfilled a personal history of invasive BC and at least one of the following criteria: A) diagnosis at age ≤ 40 years, B) BC at any age at onset with at least 2 first- and/or second-degree relatives, C) BC \< 50 years in a first- or second-degree relative, D) ovarian cancer in at least 2 first- and/or second-degree relatives, E) breast and ovarian cancer in at least 2 first- and/or second-degree relatives, F) both breast and ovarian cancer in a single first- or second-degree relative.

Approval to conduct the study was obtained from the Ethics Committee of Saint-Joseph University-Lebanon. After an informed consent was signed and all ethical requirements were fulfilled, a 10 ml of peripheral blood was isolated from each individual enrolled and the DNA was extracted using the salting out methods \[[@CR24]\]. All patients signed the informed consent and agreed to share their variant data.

Whole exome sequencing {#Sec4}
----------------------

Exon capture and sequencing: Samples were prepared for whole Exome sequencing and enriched according to the manufacturer's standard protocol. The concentration of each library was determined using Agilent's QPCR NGS Library Quantification Kit (G4880A). Samples were pooled prior to sequencing with each sample at a final concentration of 10nM. Sequencing was performed on the Illumina HiSeq2000 platform using TruSeq v3 chemistry.

Mapping and alignment: Reads files (FASTQ) were generated from the sequencing platform via the manufacturer's proprietary software. Reads were aligned to the hg19/b37 reference genome using the Burrows-Wheeler Aligner (BWA) package v0.6.1 \[[@CR25]\]. Local realignment of the mapped reads around potential insertion/deletion (Indel) sites was carried out with the Genome Analysis Tool Kit (GATK) v1.6 \[[@CR26]\]. Duplicate reads were marked using Picard v1.62. Additional BAM file manipulations were performed with Samtools 0.1.18 \[[@CR27]\]. Base quality (Phred scale) scores were recalibrated using GATK's covariance recalibration. SNP and Indel variants called using the GATK Unified Genotyper for each sample \[[@CR28]\]. SNP novelty is determined against dbSNP. A list of 134 genes known to be associated with hereditary BC and other cancers were studied (Additional file [1](#MOESM1){ref-type="media"}).

Variants evaluation {#Sec5}
-------------------

Variants obtained were reported using five categories according to the Human Genome Mutation Database (HGMD Professional) \[[@CR29]\]. These categories are listed in Table [1](#Tab1){ref-type="table"}.Table 1Variants reported in five categories according to the HGMD ProfessionalCategoryCategoryVariation reported asDMDisease-causing mutationsPathological mutationDM?Disease-causing mutationsLikely pathological mutationDPDisease-associated polymorphismPolymorphism in significant association with a disease/phenotype (*p* \< 0.05) that is assumed to be functionalDFPDisease-associated polymorphismPolymorphism in significant association with disease (*p* \< 0.05) that has evidence of being of direct functional importanceFPIn vitro/laboratory or in vivo functional polymorphismPolymorphism that affects the structure, function or expression of the gene (or gene product), but with no disease association reported as yet

The first variant category consists of alleles labeled as disease causing mutations (DM) in HGMD Professional. These alleles must be rare: \<1% allele frequency in 6,500 exomes from the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project ("Exome Variant Server" 2015) and the 1,000 Genomes Project Genomes \[[@CR30]\].

The *BRCA* gene variants identified were checked for pathogenicity in 4 databases: Breast Cancer Information Core (BIC) \[[@CR31]\], Leiden Open Variation Database (LOVD) \[[@CR32]\], the Catalogue of Somatic Mutations in Cancer database (COSMIC) \[[@CR33]\] and BRCA Exchange website ([http://brcaexchange.org](http://brcaexchange.org/)) providing data from the ENIGMA consortium \[[@CR34]\].

Variants confirmation {#Sec6}
---------------------

Sanger's sequencing was utilized to confirm the relevant variants identified by WES and to study the segregation of these variants with the disease phenotype in members of families included in the study. PCR reactions were run in final volumes of 50 μl containing 100 ng DNA, 0.25 mM dNTPs, 100 ng of each primer and 0.02 unit of Taq polymerase (Invitrogen Life Technologies, Carlsbad, CA, USA). PCR was performed in an ABI9700 thermocycler (Applied Biosystems, Foster City, CA) with initial denaturation at 94 °C for 5 min, followed by 35 cycles of 95 °C for 30s, specific annealing temperature for 30s, 72 °C for 30s. Primer sequences are available on request as well as annealing temperatures of each exon. PCR products were purified using the illustraTM GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, Buckinghamshire, UK). Both strands of the products were sequenced using the BigDyeW Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) under standard conditions. The labeled products were subjected to electrophoresis on an ABI3130 and ABI3500 Genetic Analyzer sequencing system (Applied Biosystems, Foster City, CA, USA). Electropherograms were analyzed using Sequence Analysis Software v5.2 (Applied Biosystems, Foster City, CA, USA) and compared to reference sequences using ChromasPro v1.7.6.1 (Technelysium, Queensland, Australia).

Results {#Sec7}
=======

Patient characteristics and sequencing statistics {#Sec8}
-------------------------------------------------

The mean age at diagnosis of BC for the 45 patients was 44 years (range 29--79). Sixteen patients provided us with their histopathological results. Seven BC were estrogen-receptor (ER) and progesterone-receptor (PR) positive, 5 patients had negative ER and PR disease and 2 patients had negative ER and positive PR disease. Two patients had triple negative disease from which one patient (Family 30) carried p.C44F mutation in *BRCA1* (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Pedigrees of the families presenting DM mutations. Filled squares (males) and circles (females) indicate the affected individuals. Probands are marked with arrows. DM mutations are bolded

We obtained an average of 44 million reads per sample, with a mean coverage of 94% at a mean X coverage of 20X.

WES analysis {#Sec9}
------------

Within this cohort, a total of 126 variants were detected by WES and these are listed in Table [2](#Tab2){ref-type="table"}. In 7 of the 45 patients, not listed in Table [2](#Tab2){ref-type="table"}, no variants in cancer predisposing genes (Additional file [1](#MOESM1){ref-type="media"}) were identified.Table 2Mutations in BC associated genes detected by NGS in a series of 45 Lebanese patientsFamily number/Patient codeGenesResultsHGMD ProfessionalExAC allele frequency1/B19*XRCC3*c.C722T p.T241MDFP Association with melanoma0.3075*XRCC1*c.G839A p.R280HDFP Association with increased lung cancer0.08811*CASP8*c.\*429A \> GNot foundNot found*BRCA2*c.C65T p.A22VNot foundNot found*MUTYH*c.C1258G p.L420VNot foundNot found*SLX4*c.C1837T p.Q613XNot foundNot found2/B21*BRCA1*c.A536G p.Y179CDM Breast and/or ovarian cancer0.0002718*ATM*c.T2572C p.F858LDP Association with breast cancer0.009149*ATM*c.C3161G p.P1054RDFP Association with breast cancer0.01692*TP53*c.C215G p.P72RDFP Association with Lung cancer0.66003/B22*BRCA2*c.C5744T p.T1915MDP Association with breast cancer risk0.01790*ARL11*c.G446A p.W149XDP Association with cancer0.009898*TP53*c.C215G p.P72RDFP Association with Lung cancer0.6600*ERCC3*c.C508T p.R170XNot foundNot found*VHL*c.A631C p.M211LNot found0.00004623*MRE11A*c.C1491T p.I497INot found0.0006514*PTCH1*c.G4054A p.V1352INot foundNot found4/B23*TP53*c.C215G p.P72RDFP Association with Lung cancer0.6600*TP53*c.C245T p.P82LDM Breast cancer0.00001657*BRCA2*c.A1114C p.N372HDFP Association with Breast cancer0.2779*FANCA*c.G1038C p.W346CNot found0.00006621*POLE*c.C3890T p.S1297LNot found0.00002580*POLD1*c.T2257C p.Y753HNot foundNot found*GATA2*c.C1040T p.T347INot foundNot found5/B24*BRCA2*c.G8775C p.Q2925HNot found0.000008322*APC*c.C6821T p.A2274VDM Adenomatous polyposis coli0.0009917*EZH2*c.C349T p.Q117XNot foundNot found6/B25*XRCC3*c.C722T p.T241MDFP Association with melanoma0.3075*MLH1*c.A655G p.I219VDP Colorectal cancer, non-polyposis0.2325*RAD51D*c.G494A p.R165QNot foundNot found*ATM*c.496 + 4 T \> CNot found0.00009891*PPM1D*c.G275C p.C92SNot foundNot found*STK11*c.375-1C \> TDM Colorectal cancerNot found7/B26*XRCC3*c.C722T p.T241MDFP Association with melanoma0.3075*MSH2*c.C1045G p.P349ADM Renal cell carcinoma0.00009062*MUTYH*c.C1174A p.L392MNot foundNot found*MUTYH*c.C1258A p.L420MDM? Colorectal cancerNot found*ATM*c.496 + 4 T \> CNot found0.00009891*RB1*c.C1505T p.T502INot found0.00001098*PPM1D*c.G275C p.C92SNot foundNot found8/B27*XRCC3*c.C722T p.T241MDFP Association with melanoma0.3075*BRCA1*c.A1067G p.Q356RDP Association with breast and/or ovarian cancer0.04407*XRCC1*c.C580T p.R194WDFP Benign breast disease0.09276*CDH1*c.G1774A p.A592TDM? Breast cancer0.00321235/B28*BARD1*c.1071_1091del p.357_364delNot foundNot found*ABCC12*c.G490T p.G164XDM Bladder cancer0.003185*MCC*c.G152T p.G51VNot found0.00013469/B31*ATM*c.T2119C p.S707PDFP Association with Breast cancer0.007927*FANCA*c.C4232T p.P1411LNot found0.000131836/B32*ATM*c.C2770T p.R924WNot found0.00004942*ALK*c.T4211C p.L1404PNot found0.0000837010/B33*BRIP1*c.A3571G p.I1191VNot found0.00004967*NSD1*c.2224_2243del p.P742fsNot foundNot found*FANCG*c.G1298C p.R433PNot found0.00004118*FLCN*c.T1387C p.Y463HNot found0.00003298*PTCH1*c.A3749G p.Y1250CNot foundNot found11/B34*XRCC4*c.T401C p.I134TDP Association with Lung cancer0.02505*RAD51C*c.G376A p.A126TFP Reduced activity0.00352912/B35*ARL11*c.G571A p.G191RNot found0.00002188*Rad50*c.A280C p.I94LDM? Breast and/or ovarian cancer0.003473*POLE*c.G2276A p.R759HNot found0.0000164713/B36*BRCA1*c.G131T p.C44FDM Breast and/or ovarian cancerNot found*SLX4*c.G421T p.G141WDM Breast and/or ovarian cancer0.0008237*STK11*c.C1211T p.S404FDM Peutz-Jeghers syndrome0.0009281*PALB2*c.G2993A p.G998EDP Breast cancer, increased risk-0.01579*BRCA2*c.C1151T p.S384FDM? Breast cancer0.0006789*DICER1*c.A5276G p.K1759RNot found0.00004942*CEBPA*c.T122C p.I41TNot foundNot found*RECQL4*c.G3314A p.G1105DNot found0.00543014/B37*RAD50*c.G379A p.V127INot found0.001653*CASP8*c.A1117G p.I373VNot foundNot found*RECQL4*c.C3184T p.R1062WNot found0.0003129*WRN*c.G4129A p.G1377SNot found0.0000248315/B38*BARD1*c.C119T p.A40VNot found0.00004775*PTCH1*c.169_170delCT p.57_57delNot found0.000008913*PTCH1*c.A3749G p.Y1250CNot foundNot found*PTCH1*c.C4126T p.R1376WNot foundNot found*ERCC5*c.A1904G p.H635RNot foundNot found*DICER1*c.C3811T p.L1271FNot foundNot found16/B39*CDKN2A*c.G442A p.A148TDP Association with melanoma0.02278*RAD51D*c.A758G p.E253GNot found0.01144*ERCC6*c.C2800A p.P934TDM Cockayne syndromeNot found17/B40*MSH2*c.A1787G p.N596SDM Colorectal cancer, non-polyposis0.0002558*ATM*c.A1982C p.D661ANot foundNot found*PMS2*c.G1688T p.R563LDM? Colorectal cancer, non-polyposis0.005813*GPC3*c.78_79insCCG p.P27delinsPPNot foundNot found18/B41*BRCA2*c.658_659delGT p.V220I\*DM Breast and/or ovarian cancer0.00006119*SLX4*c.G3337C p.G1113RNot found0.000008237*SMARCA4*c.C1098G p.I366MNot found0.00002715*EPHX1*c.G1040C p.R347TNot found0.0000329619/B42*wwoxtv2*c.A544G p.K182EDM? cancerNot found*ATM*c.A5558T p.D1853VDP Association with breast cancer, contralateral0.005186*RET*c.C2508T p.S836SDP Association with thyroid cancer0.04666*BRCA1*c.5090_5093delGTTA p.L1697fsNot foundNot found20/B43*PALB2*c.G2014C p.E672QDM? Breast cancer? (common variant)0.02239*PALB2*c.G2993A p.G998EDP Breast cancer (common variant)0.01579*RAD51C*c.G376A p.A126TFP Reduced activity0.003529*Tp53*c.673-36G \> CDFP Breast cancerNot found21/B44*SLX4*c.G421T p.G141WDM Breast and/or ovarian cancer0.0008237*SLX4*c.C1919A p.T640NNot foundNot found*FANCM*c.A5224G p.I1742VNot found0.008398*POLD1*c.G2793C p.K931NNot foundNot found22/B45*ATM*c.A5071C p.S1691RDM Ataxia telangiectasia0.002019*BRIP1*c.G2220T p.Q740HDM? Breast and/or ovarian cancer0.0004614*RET*c.C2508T p.S836SDP Association with thyroid cancer0.04666*FANCA*c.A796G p.T266ADP Associated with breast cancer0.516623/B46*BARD1*c.1071_1091del p.357_364delNot foundNot found*FANCA*c.C3412G p.L1138VNot found0.001533*MRE11A*c.A1728T p.R576RNot found0.000008238*SLX4*c.C1186G p.L396VNot foundNot found37/B47*SLX4*c.A5501G p.N1834SNot found0.005542*ERCC4*c.G1633C p.G545RNot found0.00000824338/B48*SDHC*c.C31T p.R11CNot found0.000008252*FANCD2*c.A1348G p.I450VNot found0.0003871*FANCF*c.C959T p.P320LNot found0.01264*TSC2*c.A2834G p.K945RNot foundNot found*DIS3L2*c.1651_1652insGGG p.A551delinsGANot foundNot found*GNAS*c.C1046T p.P349LNot foundNot found24/B49*BRCA1*c.C4327T p.R1443\*DM Breast cancerNot found*MSH2*c.C1045G p.P349ADM Renal cell carcinoma0.00009062*MSH2*c.G965A p.G322DDM? Colorectal cancer, non-polyposis0.01411*BARD1*c.G253T p.V85LNot found0.001068*NBN*c.G340T p.V114FNot foundNot found*RET*c.C2249G p.A750GNot found0.000008238*XRCC3*c.C260T p.P87LNot found0.0000628625/B50*POLH*c.A2074G p.T692ADM Xeroderma pigmentosum0.0001824*Tp53*c.673-36G \> CDFP Breast cancerNot found*CTNNB1*c.A2315G p.N772SNot found0.00003355*POLD1*c.C519G p.S173RNot found0.00921226/D1*ARL11*c.G446A p.W149XDP Association with cancer0.009898*MSH2*c.T1182G p.F394LNot found0.0000164827/D4*CHEK2*c.T470C p.I157TDFP Li-Fraumeni syndromeNot found28/D5*CDH1*c.G2387A p.R796QNot found0.0000330029/D6*BUB1B*c.A1535G p.E512GNot found0.00000823930/D7*APC*c.C2876T p.S959FNot foundNot found*BRCA1*c.G131T p.C44FDM Breast and/or ovarian cancerNot found*PRF1*c.G3A p.M1IDM Haemophagocytic lymphohistiocytosis, familialNot found31/D8*TP53*c.G469A p.V157IDM Sarcoma, adult-onset0.0000577632/III_4*CDH1*c.G3A p.M1IDM Gastric cancerNot found*BRCA2*c.C4061T p.T1354MDM Breast cancer0.000008328*BRCA2*c.G4258T p.D1420YDM? Breast and/or ovarian cancer0.00679633/D12*CDH1*c.A160G p.R54GNot found0.0000591634/D13*BRCA2*c.G223C p.A75PDM? Breast cancer0.0001650DM disease-causing mutation, DM? likely disease-causing mutation, DP disease-associated polymorphism, FP *in vitro* or *in vivo* functional polymorphism, DFP disease-associated polymorphism with additional functional evidence

We were able to detect 19 HGMD DM variations of which 9 are specifically associated with breast cancer (Table [2](#Tab2){ref-type="table"}). The distribution of the remaining variants in the HGMD categories was: 11 DM?, 11 DP, 1 FP, and 9 DFP. In addition, 75 novel variations were detected in this study (Table [2](#Tab2){ref-type="table"}).

Six *BRCA1* and *BRCA2* DM mutations were detected in 5 and 2 patients, respectively in a total prevalence of 15.5% (Table [2](#Tab2){ref-type="table"}).

Nine truncating mutations were detected in 9 different patients (Table [2](#Tab2){ref-type="table"}). Three of these mutations were DM in HGMD: The first woman carried p.R1443\* in *BRCA1*, the second one carried p.V220I\* in *BRCA2* and the third one carried p.G164X in *ABCC12* (Table [2](#Tab2){ref-type="table"}). The six remaining truncating mutations were not found in HGMD: p.Q613X in *SLX4*, p.R170X in *ERCC3*, p.Q117X in *EZH2*, p.P742fs in *NSD1*, p.357_364del in *BARD1* and p.L1697fs in *BRCA1* (Table [2](#Tab2){ref-type="table"}).

Three DM mutations were found, each one, in 2 different patients: p.C44F in *BRCA1* (Families 13 and 30), p.P349A in *MSH2* (Families 7 and 24) and p.G141W in *SLX4* (Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}).

In some families where different variants were found, in order to consider, which variant is pathogenic, we analyzed the co-segregation of the variations found with the cancer phenotype within 3 families 12, 13, and 32 (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}).Fig. 2Pedigree of one family segregated for *BRCA2* p.T1354M and *CDH1* p.M1I variants. Filled squares (males) and circles (females) indicate the affected individuals. + sign indicates the presence of the variant and -- sign the absence of the variant in tested individuals

Two members of family 12 were diagnosed with BC, their mother and maternal uncle were diagnosed with primary lung cancer and bone cancer, respectively. The nonsmoking mother was affected at the age of 63 but the age of the maternal uncle at diagnostic was not accessible. WES, in proband 12/B35 diagnosed with BC at the age of 42, identified 2 variants including one DM? p.I94L in *RAD50*, according to HGMD Professional database, and one novel variation p.G191R in *ARL11* (data not shown). Prediction tool Polyphen2 indicated that both changes are benign and SIFT prediction tool indicated that p.I94L in *RAD50* is tolerated and that p.G191R in *ARL11* is damaging. Only p.I94L in *RAD50* segregated in the affected sisters, diagnosed with BC at the age of 48, but it was also found in their third youngest 51 years old unaffected sister.

Three members of Family 13 were diagnosed with BC. WES identified 3 DM according to HGMD Professional database, including p.C44F in *BRCA1*, p.G141W in *SLX4* and p.S404F in *STK11* (Table [2](#Tab2){ref-type="table"}). Leiden Open Variation Database indicated that p.C44F in *BRCA1* affects protein function and it segregated with the disease (Table [3](#Tab3){ref-type="table"}) (Fig. [1](#Fig1){ref-type="fig"}).Table 3*BRCA* variations found and their evaluations in *BRCA* databasesGeneVariationBIC database Clinically Importance/ Clinical ClassificationCOSMICLeiden Open Variation Database (LOVD)BRCA Exchange*BRCA1*c.G131T p.C44Funknown/ pendingNot foundAffects functionNot foundc.A536G p.Y179Cunknown/ pendingNot foundDoes not affect functionBenignc.C4327T p.R1443\*yes/ class 5NeutralAffects functionNot foundc.A1067G p.Q356Runknown/ pendingPathogenicDoes not affect functionBenignc.5090_5093delGTTA p.L1697fsNot foundNot foundNot foundNot found*BRCA2*c.C65T p.A22Vunknown/pendingNot foundEffect unknownNot foundc.G223C p.A75Punknown/ pendingNot foundDoes not affect functionBenignc.658_659delGT p.V220I\*yes/ class 5Not foundAffects functionNot foundc.C4061T p.T1354Munknown/ pendingNeutralDoes not affect functionBenignc.G4258T p.D1420Yno/ pendingNeutralDoes not affect functionBenignc.C5744T p.T1915Mno/ class 1NeutralDoes not affect functionNot foundc.G8775C p.Q2925Hunknown/ pendingNot foundEffect unknownNot foundc.A1114C p.N372Hno/ class 1NeutralNot foundBenignc.C1151T p.S384Fno/ pendingNot foundNot foundBenignDescriptions of the classes in the BIC database:Class 1: Not pathogenic/low clinical significance: There is significant evidence against this variant being a dominant high-risk pathogenic mutationClass 5: Pathogenic: There is significant evidence to suggest that this variant is a dominant high-risk pathogenic mutation

Six members of family 32 were diagnosed with BC (Fig. [2](#Fig2){ref-type="fig"}). Members III-3, III-4 and III-6 were diagnosed with BC at the age of 56, 48 and 50, respectively. WES in proband III-4 identified 2 relevant variants including p.M1I in *CDH1* and p.T1354M in *BRCA2*. Prediction tool SIFT indicated that both changes are damaging and are DM according to HGMD Professional database (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). The analysis of this family showed that these variations were carried by affected and siblings that are not affected to date (Fig. [2](#Fig2){ref-type="fig"}). However, they were advised to join our screening program.

We have noted that the most frequently altered genes involved in our familial cases are DNA repair genes (Fig. [3a](#Fig3){ref-type="fig"}) and that some variants were recurrent in our cohort: p.W149X in *ARL11*, p.S836S in *RET*, p.A126T in *RAD51C*, p.T241M in *XRCC3*, p.G998E in *PALB2* and c.673-36G \> C in *TP53* (Table [2](#Tab2){ref-type="table"} and Fig. [3b](#Fig3){ref-type="fig"}). In four cases, like the 4 families shown in Fig. [1](#Fig1){ref-type="fig"}, individuals appear to co-inherit multiple cancer causing or predisposing gene mutations. Unlike, the old strategy where one stops the investigation once a pathogenic mutation was identified, NGS gives us the capability of collating all known mutations/variants in a sample, which may permit a more comprehensive understanding of the polygenic landscape model of cancer. An important question to be answered is: Does an individual in Family 13 harboring all three DM mutation have different penetrance, genotype to phenotype correlation, type or age of onset of cancer than a sibling with only one DM variant? This critical question can only be answered when we start to combine all germline variant data of cancer patients and their comprehensive phenotypes from around the world in well-curated databases.Fig. 3Frequencies of all variants in breast cancer predisposing genes from our 45 patients' cohort (**a**) and the details of the most frequent variants shown in (**b**)

Discussion {#Sec10}
==========

We identified, in 45 patients with familial BC, 19 pathogenic mutations that are DM mutations according to the HGMD Professional database (Table [2](#Tab2){ref-type="table"}). These 19 mutations were found in 13 different genes including *ABCC12*, *APC*, *ATM*, *BRCA1*, *BRCA2*, *CDH1, ERCC6*, *MSH2*, *POLH*, *PRF1, SLX4*, *STK11,* and *TP53*. Six mutations were found in *BRCA1* and *BRCA2* presenting a lower prevalence (15.5%) of deleterious *BRCA* mutations compared to the published literature \[[@CR21]--[@CR23]\].

In the Lebanese population, p.C44F mutation in the *BRCA1* gene was found twice in this study and 5 times in previous studies \[[@CR17], [@CR18]\] in a total of 7 from 367 cases studied (1.9%). In fact, 2 of 9 patients carried a deleterious BRCA mutation in a cohort of 72 patients and 3 of 14 patients carried a deleterious BRCA mutation in a cohort of 250 patients. Our findings suggest it is the most recurrent mutation in the Lebanese population.

In families 23 and 35, we identified the truncating mutation p.357_364del in *BARD1* (Table [2](#Tab2){ref-type="table"}). A previous study, on this variation, showed the absence of co-segregation with the disease and it was considered as neutral polymorphisms \[[@CR35]\]. We have observed this variant in our population and breast cancer patients and it is recommended that a more thorough and functional examination of this variant be conducted in the future.

In families 12, 13 and 32, we identified 7 variants in *ARL11*, *BRCA1*, *BRCA2, CDH1, RAD50, SLX4*, and *STK11*. The association of which variation towards increasing predisposition to BC remains unknown. Therefore, we analyzed the segregation of these variations and BC within the families. In family 13, only p.C44F in *BRCA1* segregated with BC in the family. In family 12, p.I94L in *RAD50* (a DM? mutation) was found in affected and healthy sisters and could therefore not lead to a conclusion regarding predisposition to BC. In family 32, p.M1I in *CDH1* and p.T1354M in *BRCA2* are implicated in gastric cancer and BC respectively and knowing that the family presented with only BC, two hypothesis can be formulated. First, III-6 can be considered as phenocopy and second healthy, till now, sisters III-5, III-7 and III-9 are at high risk (Fig. [2](#Fig2){ref-type="fig"}). In fact, in high-risk families, women testing negative for the familial *BRCA* mutation have an increased risk of BC and should be considered for continued surveillance \[[@CR36]\]. Interestingly, two members of this family, III-4 and III-6 presented with invasive lobular breast cancer (Fig. [2](#Fig2){ref-type="fig"}). The association between *CDH1* gene mutation and lobular cancer has been well established previously \[[@CR37]\], and it is not unrealistic to suggest that this *CDH1* variant may be the cause of lobular breast cancer in this family.

The pathogenic status of the majority of novel substitutions found and the 6 variations considered as DM? according to HGMD professional, remains problematic (Table [2](#Tab2){ref-type="table"}). In fact, HGMD professional reports DM? as likely pathological mutation reported to be disease causing in the corresponding report, but the author has indicated that there may be some degree of doubt, or subsequent evidence has come to light in the literature, calling the deleterious nature of the variant into question \[[@CR29]\]. Further studies are needed to define the pathogenic status of the novel substitutions and the DM? variations that have been found in our cohort of patients with BC. These future studies have to be analyzed in a larger number of affected families and control population samples.

NGS and traditional sequencing methods are not proficient in detecting *BRCA* genomic rearrangements including large deletions or duplications. Deletion and duplication genomic rearrangements vary significantly among countries and within ethnic groups \[[@CR38]\]. We admit, therefore, that our reported *BRCA* mutation prevalence is underestimated.

Among the DM mutations found, several were associated with syndromes (Peutz-Jeghers), different cancer types (renal cell carcinoma, gastric cancer) and with diseases (Xeroderma pigmentosa, ataxia telangiectasia) (Table [2](#Tab2){ref-type="table"}). Clinically, none of the symptoms found in these diseases were manifested in the different studied families except for family 24. In this family, proband 24/B49 carried the mutation p.R1443\* in *BRCA1* and two *MSH2* variants (Fig. [1](#Fig1){ref-type="fig"}). Her mother had ovarian cancer and her sister uterine cancer, both are deceased and could not consequently be tested for these variants. *MSH2* mutation is reported in families with endometrial cancer (Lynch syndrome) and breast cancer from Kuwait \[[@CR39]\].

This is the first application of NGS on BC in Lebanon. In this study, we showed that the prevalence of deleterious *BRCA* mutations (15.5%) is lower than expected \[[@CR17], [@CR18]\] and that the overall mutation prevalence is equal to 40%, justifying the urgent need for the adoption of high-throughput NGS technologies to identify genes responsible for familial BC in the Lebanese population. Indeed, additional to *BRCA* mutations, highly penetrant mutations in genes associated with various hereditary cancer syndromes, such as *CDH1*, *TP53*, *MSH2, ATM* and *POLH* were found in the Lebanese population. Finally, we cannot rule out that some of these families shift a putative explanation towards a polygenic model where moderate and low penetrance alleles, acting together, may play a predominant role \[[@CR20], [@CR40], [@CR41]\]. Our findings support the eligibility of performing genetic testing by massively parallel sequencing on Lebanese familial BC cases. Moreover, we would like to use this technology for tumor genome sequencing, in order to identify somatic alterations, which would be a valuable guidance towards individualized cancer therapy of Lebanese patients with BC. However, it is worthy of note that our study reports a small number of variants that are clinically actionable. Given the high rate of novel variants identified in *BRCA1/2* and other breast cancer-associated genes, the clinical usefulness of the data is currently limited. Unless larger and rigorous studies are committed in this area of the world to correctly classify variants identified here or in other studies, the diagnosis and treatment of breast cancer will remain suboptimal.

Conclusion {#Sec11}
==========

This is the first study that utilized NGS technology to study genetic variants in 45 patients with familial breast cancer from Lebanon. Our deleterious mutation prevalence was 40% with only 15.5% accounted for by the *BRCA1* and *BRCA2* genes. This data should encourage a different strategy for familial breast cancer genetic screening in Lebanon, one that is based on WES rather than the initial screening of *BRCA1/2* genes. We report here novel and rare variants in breast cancer predisposing genes, which will be valuable to researchers and clinicians around the world for variants' classification and patients' care in general.
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===============

Additional file 1:Cancer genes explored in this study. (DOCX 11 kb)
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